Literature DB >> 10515418

Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis.

K Iyonaga1, M Suga, T Yamamoto, H Ichiyasu, H Miyakawa, M Ando.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disease of unknown aetiology characterized by accumulations of lipoproteinaceous material within the alveoli. The alveolar macrophages become increasingly foamy, and are thought to have a role in the pathogenesis of PAP. However, the mechanisms of macrophage recruitment are unclear. In the bronchoalveolar lavage fluid (BALF) of four patients with PAP and 20 normal control subjects, the following were examined: the monocyte chemotactic activity due to the chemokine monocyte chemoattractant protein (MCP)-1 with the use of a chemotactic chamber assay, the levels of MCP-1 by enzyme-linked immunosorbent assay, and the MCP-1 expression on lavage cells by immunocytochemistry and in situ hybridization. The monocyte chemotactic activity in the BALF of the PAP patients was markedly elevated, and the activity was completely absorbed by treatment with anti-MCP-1. The MCP-1 levels in the BALF were surprisingly high in the PAP group (25,100+/-472 pg x mL(-1)), whereas low levels of MCP-1 were detected in the normal control subjects (mean: never smokers 4.8; smokers 10.4 pg x mL(-1)). MCP-1 protein and messenger ribonucleic acid were expressed by macrophages from the PAP patients, and the expression was reduced according to foaming of the cells; there were monocyte-like macrophages with strong expression, small foamy cells with moderate expression, large foamy cells with a faint expression of MCP-1, and ghost cells with no expression. However, the increase of macrophage number in the PAP BALF was relatively small. These data suggest that monocyte chemoattractant protein(-1) expression by alveolar macrophages represents an amplification mechanism for the recruitment of additional macrophages to the alveoli in pulmonary alveolar proteinosis. It is possible that an ingestion of an excess of alveolar materials in pulmonary alveolar proteinosis may impair the macrophage function and the survival, resulting in the lack of a prominent increase in the macrophage number in bronchoalveolar lavage fluid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515418     DOI: 10.1034/j.1399-3003.1999.14b24.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

Review 1.  The molecular basis of pulmonary alveolar proteinosis.

Authors:  Brenna Carey; Bruce C Trapnell
Journal:  Clin Immunol       Date:  2010-03-25       Impact factor: 3.969

2.  T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung.

Authors:  Shoichi Iriguchi; Norihiro Kikuchi; Shin Kaneko; Emiko Noguchi; Yuko Morishima; Masashi Matsuyama; Keigyou Yoh; Satoru Takahashi; Hiromitsu Nakauchi; Yukio Ishii
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

3.  Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy.

Authors:  Takuji Suzuki; Takuro Sakagami; Lisa R Young; Brenna C Carey; Robert E Wood; Maurizio Luisetti; Susan E Wert; Bruce K Rubin; Katharine Kevill; Claudia Chalk; Jeffrey A Whitsett; Carrie Stevens; Lawrence M Nogee; Ilaria Campo; Bruce C Trapnell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 4.  Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis.

Authors:  Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2010-09       Impact factor: 4.806

5.  Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.

Authors:  Fabian P S Yu; Diana Islam; Jakub Sikora; Shaalee Dworski; Jiří Gurka; Lucía López-Vásquez; Mingyao Liu; Wolfgang M Kuebler; Thierry Levade; Haibo Zhang; Jeffrey A Medin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-22       Impact factor: 5.464

6.  Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population.

Authors:  Min Kwang Byun; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Jae Jeong Shim; Seung Ick Cha; Soo-Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Moo Suk Park
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

7.  Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism.

Authors:  Anna D Baker; Anagha Malur; Barbara P Barna; Shobha Ghosh; Mani S Kavuru; Achut G Malur; Mary Jane Thomassen
Journal:  J Lipid Res       Date:  2010-01-11       Impact factor: 5.922

Review 8.  Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages.

Authors:  Bruce C Trapnell; Brenna C Carey; Kanji Uchida; Takuji Suzuki
Journal:  Curr Opin Immunol       Date:  2009-09-30       Impact factor: 7.486

9.  Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.

Authors:  Anagha Malur; Mani S Kavuru; Irene Marshall; Barbara P Barna; Isham Huizar; Reema Karnekar; Mary Jane Thomassen
Journal:  Respir Res       Date:  2012-06-14

10.  Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.

Authors:  Takuji Suzuki; Takuro Sakagami; Bruce K Rubin; Lawrence M Nogee; Robert E Wood; Sarah L Zimmerman; Teresa Smolarek; Megan K Dishop; Susan E Wert; Jeffrey A Whitsett; Gregory Grabowski; Brenna C Carey; Carrie Stevens; Johannes C M van der Loo; Bruce C Trapnell
Journal:  J Exp Med       Date:  2008-10-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.